Rhabdomyolysis induced by bezafibrate
10.3760/cma.j.cn114015-20210218-00182
- VernacularTitle:苯扎贝特致横纹肌溶解症
- Author:
Junyan GONG
1
;
Bo ZHAO
;
Ruonan LI
;
Jinwei AI
;
Xingjian ZHOU
Author Information
1. 湖北医药学院附属襄阳市第一人民医院内分泌科，襄阳 441000
- Publication Type:Journal Article
- Keywords:
Bezafibrate;
Rhabdomyolysis;
Case report
- From:
Adverse Drug Reactions Journal
2021;23(12):668-670
- CountryChina
- Language:Chinese
-
Abstract:
A 55-year-old female patient took acarbose, benazepril, and levamlodipine besylate intermittently and aspirin enteric-coated tablets and atorvastatin calcium regularly due to type 2 diabetes mellitus and hypertension, etc. After changing to bezafibrate for lipid-lowering and Gansulin 30R for glucose lowering (other treatments continued), the patient developed muscle soreness of both lower limbs and dark brown urine 7 days later. Laboratory tests showed aspartate aminotransferase (AST) 213 U/L, creatine kinase (CK) 8 655 U/L, CK-MB 555 U/L, lactate dehydrogenase (LDH) 579 U/L, α-hydroxybutyrate dehydrogenase (α-HBDH) 505 U/L, and myoglobin (MYO) 135 μg/L. Rhabdomyolysis was considered, which might be related to bezafibrate. Then bezafibrate was stopped. The patient was asked to drink plenty of water and urinate frequently, and the symptomatic and supportive treatments such as rehydration, alkalization of urine, liver protection, and kidney protection were given. After 11 days of drug withdrawal, her symptom of muscle soreness was relieved and the color of urine became lighter; laboratory tests showed CK 105 U/L and MYO 119 μg/L. After 18 days of drug withdrawal, the patient′s myalgia disappeared, urine color returned to normal; laboratory tests showed AST 37 U/L, CK 75 U/L, CK-MB 45 U/L, MYO 75 μg/L, and LDH 241 U/L.
